Altria's Investment in Juul Valued at $450 Million

Aug.02.2022
Altria's Investment in Juul Valued at $450 Million
Altria's 35% stake in Juul, the leading e-cigarette manufacturer, has decreased in value by 95% due to increasing safety concerns.

Juul became the global leader in electronic cigarette manufacturing in 2018, with its products gaining widespread popularity. Virginia-based tobacco brand Altria did not want to miss out on the opportunity presented by the rapidly growing e-cigarette market and acquired a 35% stake in Juul for 12.8% of the price. At the time, Altria firmly believed that e-cigarettes represented the future of tobacco use worldwide, and Juul was leading the way towards this promising future.


However, the reality is quite different. Recently, reports claiming that electronic cigarettes are just as dangerous as traditional smoking have dampened enthusiasm for the market, sending shockwaves throughout the entire industry. Even Juul, once the world's most valuable e-cigarette company, has seen its valuation drop following concerns raised by the FDA about the safety of its products, despite a recent investment from Altria.


Tobacco company Altria's investment in Juul is now valued at $450 million, less than 5% of the e-cigarette maker's 2018 valuation. Earlier this year, Altria lowered its valuation of Juul to $1.6 billion as the US Food and Drug Administration began reviewing Juul's products. In its Q2 earnings report, Altria further reduced the valuation by $1.2 billion, putting the new value at $450 million. Despite the drastic reduction, Altria says it has no plans to work with Juul and will honor its original agreement not to launch any new e-cigarette products or invest in other e-cigarette companies. "We made the decision not to make any different decisions," said Altria CEO Billy Gifford. "We believe the right decision at this point in time is to maintain noncompetition.


The rapid decline in Juul's valuation is due to the FDA's decision last month to ban Juul e-cigarettes, as the company failed to provide key information about its nicotine formula. This surprised many as the FDA has approved many similar products. While Juul received criticism from a federal court to continue selling its products, the FDA has re-examined the company's application and frozen its ban. This means that the future of Juul's products remains uncertain in the foreseeable future.


The FDA's decision stems from recent studies that indicate e-cigarettes are harmful to users and pressure from advocacy groups who believe these products are just as bad as traditional tobacco products. Therefore, the FDA is working to eliminate products that do not help smokers quit. Juul's various flavors and brightly colored packaging are attractive to non-smokers. Aside from its valuation, Juul's current issues have also led to a nearly 60% decrease in Altria's earnings to 49 cents per share. This has caused a 6% decrease in quarterly revenue to around $6.5 billion. Altria is the largest cigarette manufacturer in the US and, as smoking rates decline, the company is fighting hard in the Juul and future e-cigarette market.


This article is compiled from third-party information and is only for industry exchange and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot verify the truthfulness or accuracy of the content. The translation of this article is intended for industry-related discussions and research purposes only.


Due to limitations in translation capabilities, the translated article may not express the original meaning accurately. Please refer to the original article for accuracy.


2FIRSTS aligns completely with the Chinese government's views and positions on all domestic, Hong Kong, Macau, Taiwan, and international matters.


The compilation of information belongs to the original media outlet and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

 FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
The U.S. Food and Drug Administration (FDA) has initiated scientific review of renewal applications for 22nd Century Group’s VLN reduced-nicotine cigarettes under the Modified Risk Tobacco Product (MRTP) pathway, with current authorizations set to expire in December 2026.
News
May.13
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Special Report|Haypp’s Nicotine Pouch Volumes Rise 40%: Who Controls the Digital Shelf for Modern Oral?
Haypp Group reported a 40% year-on-year increase in nicotine pouch volumes in the first quarter of 2026, with U.S. and U.K. volumes rising 123% and 102%, respectively. Haypp says around 97% of its consumer traffic is organic and that its Media & Insights business provides brand owners with on-site visibility, trial activation and consumer intelligence. For international tobacco companies, Haypp may be both a growth partner for modern oral products and a new source of channel leverage.
Special Report
May.22
PML Expands Its UK Smoke-Free Portfolio With LEVIA
PML Expands Its UK Smoke-Free Portfolio With LEVIA
Philip Morris Limited has launched LEVIA, a new range of zero-tobacco flavored nicotine sticks created for the IQOS ILUMA range. The product expands the company’s smoke-free portfolio in the UK and will initially be available in four variants, including Deep Mint and three capsule-based flavors. LEVIA has a recommended retail price of £5, or about $6.73, based on the European Central Bank’s April 28.
Apr.29 by 2FIRSTS.ai
KT&G Launches “Miix Cigar Collection” for lil Hybrid at Convenience Stores Nationwide
KT&G Launches “Miix Cigar Collection” for lil Hybrid at Convenience Stores Nationwide
KT&G said on April 15 that it will launch “Miix Cigar Collection,” a dedicated stick for its lil Hybrid heated tobacco product, at convenience stores nationwide in South Korea. The company said the product is the first in the Miix series to apply a “Balance Filter” with internal space in the filter and contains 18% cigar leaf to deliver cigar flavor. With the new launch, the Miix lineup for lil Hybrid will expand to 16 products.
Apr.15 by 2FIRSTS.ai
UK Bill Banning Tobacco Sales to People Born After 2008 Clears Parliament
UK Bill Banning Tobacco Sales to People Born After 2008 Clears Parliament
A UK bill banning the legal sale of tobacco to people born on or after January 1, 2009 has completed its passage through parliament. Under the bill, those born in that group will never be able to be legally sold tobacco anywhere in the UK. The legislation is expected to receive royal assent next week. It also gives ministers powers to strengthen public-place smoking restrictions and restricts branding, promotion and advertising of vape and nicotine products aimed at children.
Apr.22 by 2FIRSTS.ai
BAT Malaysia Launches Workforce Exercise to Improve Efficiency and Align With Future Business Direction
BAT Malaysia Launches Workforce Exercise to Improve Efficiency and Align With Future Business Direction
British American Tobacco Malaysia has announced a workforce optimisation exercise aimed at streamlining operations ahead of a major shift in its distribution strategy.
Apr.01 by 2FIRSTS.ai